Skip to main content

Prosthetic Infection and Biofilm Protocols

Prosthetic infections in urology — inflatable penile prosthesis (IPP), artificial urinary sphincter (AUS), and pelvic mesh — are governed by a pharmacology fundamentally different from soft-tissue or urinary-tract infection. Bacteria and fungi adherent to synthetic surfaces form biofilms that confer antibiotic tolerance orders of magnitude greater than the planktonic state, rendering standard MIC-based antimicrobial therapy inadequate and making infection prevention far more important than infection treatment. Once a device is colonized, removal or salvage — not antibiotics alone — is almost always required.[1][2]

This article is the pharmacology-oriented synthesis of protocols that sit at the interface of perioperative antimicrobial prophylaxis, dipping / irrigation solutions, and device-specific chemistry. For the surgical-technique deep-dive on IPP infection, see Penile implants — infection; for the general perioperative framework, see Perioperative antibiotic prophylaxis.

Biofilm biology — why prosthetic infections are different​

Within hours of implantation, planktonic bacteria and fungi adherent to a synthetic surface secrete an extracellular polymeric matrix that:

  • Reduces antibiotic penetration to the encased cell population
  • Induces a low-metabolic-activity subpopulation (persister cells) refractory to cell-wall-active and protein-synthesis-targeting agents
  • Facilitates horizontal gene transfer of resistance determinants
  • Is disrupted mechanically more effectively than chemically — which is the rationale for jet-irrigation approaches

The clinical consequence is that tissue-MIC-based dosing does not apply once biofilm is established. Prevention — eliminating contamination at the moment of implantation — carries far more leverage than post-infection treatment does.[1][2]

The contemporary microbial landscape​

Contemporary device-infection microbiology has shifted meaningfully over two decades. The Gross 2017 multicenter IPP-infection cultures analysis defined the current spectrum:[3]

Organism classApproximate share of modern IPP infections
Coagulase-negative StaphylococcusHistorically dominant; now reduced by antibiotic-impregnated coatings
MRSA~10%
Gram-negative organismsIncreasing share
Candida spp. (albicans, glabrata)Up to 11%
PolymicrobialCommon in revision / salvage

A dedicated review of fungal IPP infections found 83% occur in diabetic or obese patients.[4] The antibiotic regimens recommended by the original 2008 AUA BPS — extrapolated from orthopedic and general-surgery literature — target the older microbial spectrum and are increasingly mismatched to the organisms that actually cause modern device infections.

IPP prophylaxis — the PUMP reassessment​

The Prosthetic Urology Multi-Institutional Partnership (PUMP) has produced the most consequential challenge to standing AUA IPP prophylaxis recommendations. Two datasets together define the current evidence:

  • Barham 2023 (J Urol, PUMP, 4,161 primary IPPs) — vancomycin + gentamicin alone was associated with a 2.7-fold higher infection risk than nonstandard regimens (HR 2.7; 95% CI 1.4–5.4; p = 0.004).[5]
  • Abou Chawareb 2025 (5,261 patients, 16 centers) — IV antifungal use was independently associated with significantly lower infection risk (OR 0.22; p < 0.001). Postoperative oral antibiotics and IV prophylaxis >24 h showed no protective effect. Diabetes (OR 1.68) and prior IPP infection (OR 4.67) were the dominant patient-level risk factors.[6]
  • Rezaee 2020 (diabetic subgroup) — AUA-adherent prophylaxis yielded 5.6% infection rates vs 1.9% for nonstandard regimens in diabetic primary IPPs. Effective alternatives included vancomycin-gentamicin-fluoroquinolone, clindamycin-fluoroquinolone, and vancomycin-fluoroquinolone combinations.[7]

Practice-pattern gap: Brant 2023 national-cohort data show a 42% relative increase in AUA-adherent vancomycin-plus-gentamicin regimen use after the BPS publication — widespread adoption of a regimen now shown to be inferior.[8] The 2025 Sex Med Rev from the 5th International Consultation on Sexual Medicine is the current expert-consensus counterpoint pending formal BPS revision.[9]

Modern contemporary IPP regimen​

Five principles, all supported by current PUMP data:

PrinciplePractical
1. Tailor to local antibiogramPull institutional Candida and gram-negative resistance data; ideal regimen varies by institution
2. Cover MRSA, gram-negatives broadly, and CandidaVancomycin + gram-negative agent + fluconazole 400 mg IV is the defensible default
3. Single perioperative dose, stop within 24 hPUMP 2025 shows no benefit to extended IV or postop oral[6]
4. Within 60 min of incisionCephalosporins 30–60 min; vancomycin within 120 min (longer infusion)
5. Skip routine postop oral antibioticsConfirmed no protective benefit — Dropkin 2020 + PUMP 2025[6][10]

Gross group published regimen: vancomycin + piperacillin-tazobactam + fluconazole.[4] Gram-negative agent substitution (gentamicin, pip-tazo, or ceftriaxone) is local-antibiogram-driven.

Adoption patterns — SMSNA/SUPS/GURS 2025 survey — antifungal use: 25.9% primary, 72.3% diabetic, 65.2% salvage, 48.2% revision cases.[11] Addition of antifungal to hydrophilic-dip solutions does not compromise antibacterial activity on bench testing.[12]

See Antifungals for the detailed case for fluconazole in IPP surgery.

Device-specific dipping — InhibiZone vs hydrophilic Titan​

Dipping / irrigation chemistry is fundamentally device-specific. Confusing the two is a common — and consequential — error.

AMS 700 InhibiZone (Boston Scientific)​

  • Factory-applied rifampin + minocycline coating covalently bonded to silicone; elutes over 24–72 h
  • Do NOT dip — the manufacturer's IFU explicitly prohibits antibiotic soaking because it strips the factory coating
  • Irrigate the surgical field instead, with sterile saline, antibiotic-fortified saline (vancomycin 1 g/L + gentamicin 80 mg/L), or 0.05% chlorhexidine gluconate (see Irrisept section)
  • Carson 2004 registration data: infection 1.61% → 0.68% at 6 months; Carson 2011 confirmed durability out to 7.7 y[13][14]

Coloplast Titan (hydrophilic)​

  • Polyvinylpyrrolidone (PVP) surface that absorbs surgeon-applied antibiotic solution
  • Dip for ≥30 seconds immediately before placement — the surgeon's dip IS the infection protection
  • Vancomycin 1 g/L + gentamicin 80–160 mg/L is the best-evidenced combination; Towe 2020 showed it superior to rifampin-gentamicin, bacitracin-polymyxin-gentamicin, and TMP-SMX-gentamicin in diabetic patients (1.4% vs up to 6.4% infection)[15]
  • Antifungal (fluconazole or AmB) can be added to the dip in high-risk patients without compromising antibacterial activity[12]
  • Wolter & Hellstrom 2004 registration data: infection 2.07% → 1.06% at 1 year; Serefoglu 2012 confirmed durability out to 11 y[16][17]

Irrisept (0.05% chlorhexidine gluconate) — the 2026 device-specific pivot​

Irrisept is a self-pressurized lavage containing 0.05% CHG in sterile water, FDA-cleared as an antimicrobial wound-irrigation device. Its mechanism is attractive:

  • Cationic CHG binds anionic microbial cell-wall components → rapid broad-spectrum kill (gram-positive, gram-negative, anaerobes, fungi including Candida, enveloped viruses)[18]
  • Mechanical jet lavage adds physical biofilm disruption
  • Low tissue toxicity, no meaningful systemic absorption
  • Does not promote antibiotic resistance — a stewardship plus

Device-specific outcomes — the critical point​

Ivan 2026 published two matched studies that together define the current practice consensus:

DeviceCHG vs antibiotic-only irrigationPractical
AMS 700 InhibiZone (n = 761)No difference — 1.9% CHG vs 2.0% antibiotic (p = 0.9)[19]Safe to use — CHG adds biofilm disruption without degrading the covalent rifampin-minocycline coating
Coloplast Titan (hydrophilic, n = 2,150)Higher infection — 4.6% CHG vs 2.1% antibiotic (p < 0.05); 12% in revision subgroup[20]Avoid — CHG appears to displace the surgeon-applied antibiotic dip from the PVP surface

Mechanistic explanation (Simhal 2024, in vitro): vancomycin-gentamicin dipping confers ~5.5 log microbial reduction on hydrophilic surfaces, while 0.05% CHG alone provides only ~1.5 log reduction.[21] The CHG effect on InhibiZone is additive; on hydrophilic Titan it is subtractive.

Corroborating data — Helo 2025 identified CHG application, diabetes, revision surgery, and extended operative time as independent risk factors for IPP infection when stacked.[22] Karpman 2023 and Lim 2024 bench work confirmed InhibiZone retains activity after CHG exposure.[18][23]

Practice implication: for hydrophilic Titan cases, use vancomycin-gentamicin fortified saline irrigation, not CHG, pending the NCT06489431 Rush prospective trial (Irrisept vs antibiotic irrigation for virgin IPP placement, readout 2026–2027).

Solutions to avoid​

  • Povidone-iodine wound irrigation — Manka 2020 case-control: 9 to 16.9-fold increased infection risk with 5% betadine wound irrigation vs antibiotic saline. Povidone-iodine remains appropriate for skin preparation, not wound irrigation.[24]
  • Hydrogen peroxide — tissue cytotoxicity, impaired wound healing, documented risk of corporal air embolism. Dropped from the modern Mulcahy salvage protocol.
  • Bacitracin-polymyxin or TMP-SMX-gentamicin dips on hydrophilic devices — Towe 2020 showed inferior to vancomycin-gentamicin.[15]
  • 0.05% CHG on hydrophilic Titan devices — Ivan 2026 data as above.[20]

AUS prophylaxis​

  • Similar device-infection mechanism to IPP — biofilm-forming skin flora and gram-negatives dominate
  • Guideline adherence lower than IPP — Sun 2023 20-year national cohort (n = 9,775) found only 44.1% received AUA-adherent prophylaxis (vancomycin + gentamicin), though adherence trending up (+7.7%/year). Guideline-adherent regimens reduced any complication (OR 0.83) and revision (OR 0.85) at 90 days, but not infection specifically (OR 0.89; 95% CI 0.68–1.17) — consistent with the PUMP signal that vancomycin + gentamicin alone is mechanistically insufficient[25]
  • Typical contemporary regimen — vancomycin + gram-negative agent + fluconazole 400 mg IV (particularly in diabetic or redo patients); chlorhexidine skin prep; no-touch technique; no drain
  • IDSA 2019 ASB guideline — do NOT screen or treat asymptomatic bacteriuria before AUS implantation (weak recommendation; very low evidence) — device infections are caused by biofilm-producing skin flora, not urinary pathogens[26]

Mesh and sacrocolpopexy​

  • Cefazolin 2 g IV is standard for vaginal-approach SUI sling and POP repair with mesh
  • Cefazolin + metronidazole for abdominal / robotic sacrocolpopexy crossing the peritoneum
  • MRSA nasal screening + mupirocin/chlorhexidine decolonization in carriers before mesh placement (borrowed from orthopedic prosthetic practice)
  • Chlorhexidine skin prep on abdominal field; vaginal prep with 4% CHG or 1% povidone-iodine per surgeon preference
  • The PUMP antifungal signal has not been formally extended to mesh surgery, but biologic plausibility supports antifungal addition in diabetic and high-risk patients

Salvage — the Mulcahy washout​

Modified-Mulcahy protocol (for suspected or confirmed IPP infection):

  1. Explant all prosthesis components
  2. Sequential antiseptic washes — avoid hydrogen peroxide and excess povidone-iodine in modern practice
  3. Change all gloves and instruments between explant and reimplant phases
  4. Re-prep and re-drape the field
  5. Replace with a new antibiotic-coated implant

Contemporary 2026 considerations​

  • Capsule and pseudocapsule cultures sent routinely; next-generation sequencing where available — biofilm organisms frequently do not grow on conventional culture
  • Fresh antibiotic-coated device used even in presumed non-infectious revisions
  • Antifungal coverage added routinely in salvage and revision settings given Abou Chawareb OR 0.22 and fungal prevalence up to 11%[4][6]
  • 0.05% CHG specifically avoided in revisions involving hydrophilic devices given the 12% infection rate in this subgroup in Ivan 2026[20]
  • Historical revision infection rates 10–13% have been brought down to ~3% in experienced hands with modern washout
  • Prior IPP infection is the single largest patient-level risk factor (OR 4.67 in Abou Chawareb 2025)[6]

Evidence Summary​

IndicationEvidence levelKey trial / guidelineNotes
IPP prophylaxis — modern evidenceLevel 1PUMP 2023 / 2025[5][6]Vanc + gent alone 2.7× higher infection; IV antifungal OR 0.22
Postop antibiotics after IPPLevel 2Dropkin 2020[10]; PUMP 2025[6]No benefit — do not prescribe
AUA-adherent vs alternatives in diabeticsLevel 3Rezaee 2020[7]5.6% vs 1.9% infection favoring nonstandard regimens
InhibiZone coatingLevel 1Carson 2004[13] / 2011[14]1.61% → 0.68% at 6 mo; durable ≥7.7 y
Titan hydrophilic dippingLevel 2Wolter 2004[16]; Towe 2020[15]Vanc 1 g/L + gent 80–160 mg/L superior
CHG (Irrisept) on InhibiZoneLevel 3Ivan 2026[19]; Karpman 2023[18]; Lim 2024[23]Safe; coating retained
CHG on hydrophilic TitanLevel 3Ivan 2026[20]; Helo 2025[22]; Simhal 2024[21]Avoid — 4.6% vs 2.1% infection; 12% revision rate
AUS prophylaxis adherenceLevel 3Sun 2023 national cohort[25]Improves complication and revision, not infection
Povidone-iodine wound irrigationLevel 3Manka 2020[24]Avoid — 9–17× higher infection

Clinical Positioning​

  • The AUA vancomycin + gentamicin IPP recommendation is now actively inferior in PUMP-scale data. Build a contemporary regimen around vancomycin + gram-negative agent (local antibiogram) + fluconazole 400 mg IV, single dose, stopped within 24 h.[5][6]
  • Antifungal prophylaxis is the strongest modifiable signal in IPP infection prevention — OR 0.22 for IV antifungal use. Add fluconazole to every primary IPP in diabetic, obese, or revision patients; strongly consider in all primaries.[6]
  • Never skip AUA-adherent prophylaxis based on PUMP data alone without a deliberate regimen substitution — nonstandard ≠ inadequate. Ensure your alternative covers MRSA, gram-negatives, and Candida.[5][7]
  • InhibiZone — do not dip. Titan — dip vanc 1 g/L + gent 80 mg/L for ≥30 s. Treating these interchangeably is a preventable error.[13][15]
  • Irrisept is device-specific. Safe on InhibiZone; avoid on hydrophilic Titan, particularly revision cases, based on Ivan 2026.[19][20]
  • Povidone-iodine is skin prep, not wound irrigation. Hydrogen peroxide is obsolete. Both were once routine, neither belongs in the modern wound.[24]
  • No postoperative oral antibiotics after IPP or AUS. Multiple datasets now converge: no benefit, stewardship harm.[6][10]
  • Do not screen or treat asymptomatic bacteriuria before IPP or AUS — IDSA weak recommendation; device infection microbiology is skin biofilm, not urinary pathogens.[26]
  • MRSA nasal screening + decolonization in carriers before any prosthetic device surgery.
  • In revision / salvage — fresh antibiotic-coated device, antifungal coverage, cultures (including NGS where available), and specifically avoid CHG on hydrophilic devices. Prior infection is the single largest patient-level risk factor (OR 4.67) — counsel accordingly.[6]
  • Build a personal infection registry. The PUMP investigators generated the evidence reshaping the field by tracking their own outcomes systematically — your center can do the same.

See Also​

References​

1. Wilson SK, Costerton JW. "Biofilm and penile prosthesis infections in the era of coated implants: a review." J Sex Med. 2012;9(1):44–53. doi:10.1111/j.1743-6109.2011.02428.x

2. Eid JF. "Penile implant: review of a 'no-touch' technique." Sex Med Rev. 2016;4(3):294–300. doi:10.1016/j.sxmr.2016.01.002

3. Gross MS, Phillips EA, Carrasquillo RJ, et al. "Multicenter investigation of the microorganisms involved in penile prosthesis infection: an analysis of the efficacy of the AUA and EAU guidelines for penile prosthesis prophylaxis." J Sex Med. 2017;14(3):455–463. doi:10.1016/j.jsxm.2017.01.007

4. Natsos A, Tatanis V, Lekkou A, et al. "Unveiling the hidden perils: a comprehensive review of fungal infections in inflatable penile prosthesis surgery." J Pers Med. 2024;14(6):644. doi:10.3390/jpm14060644

5. Barham DW, Pyrgidis N, Gross MS, et al. "AUA-recommended antibiotic prophylaxis for primary penile implantation results in a higher, not lower, risk for postoperative infection: a multicenter analysis." J Urol. 2023;209(2):399–409. doi:10.1097/JU.0000000000003071

6. Abou Chawareb E, Hammad MAM, Azad B, et al. "Perioperative antimicrobial strategies in inflatable penile prosthesis surgery: associations between antifungals, oral antibiotics, and intravenous antibiotic duration, and infection outcomes." J Urol. 2025;214(6):642–653. doi:10.1097/JU.0000000000004716

7. Rezaee ME, Towe M, Osman MM, et al. "A multicenter investigation examining American Urological Association recommended antibiotic prophylaxis vs nonstandard prophylaxis in preventing device infections in penile prosthesis surgery in diabetic patients." J Urol. 2020;204(5):969–975. doi:10.1097/JU.0000000000001158

8. Brant A, Lewicki P, Punjani N, et al. "Trends in antimicrobial prophylaxis for inflatable penile prosthesis surgery from a large national cohort." Urology. 2023;172:131–137. doi:10.1016/j.urology.2022.11.010

9. Köhler T, Munarriz R, Parker J, et al. "Penile prosthesis for erectile dysfunction: recommendations from the 5th International Consultation on Sexual Medicine." Sex Med Rev. 2025;13(2):144–171. doi:10.1093/sxmrev/qeaf001

10. Dropkin BM, Chisholm LP, Dallmer JD, et al. "Penile prosthesis insertion in the era of antibiotic stewardship — are postoperative antibiotics necessary?" J Urol. 2020;203(3):611–614. doi:10.1097/JU.0000000000000578

11. Abou Chawareb E, Barham DW, Hammad MAM, et al. "Multicenter examination of contemporary penile prosthesis surgery infection prophylaxis practices." J Sex Med. 2025;22(8):1531–1533. doi:10.1093/jsxmed/qdaf145

12. Im B, Giordano A, Winslow A, Hickok N, Chung P. "Addition of antifungal agents to antibiotic solutions does not diminish the antibacterial properties of penile prosthesis hydrophilic surface dips." J Sex Med. 2026;23(2). doi:10.1093/jsxmed/qdaf372

13. Carson CC. "Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants." J Urol. 2004;171(4):1611–1614. doi:10.1097/01.ju.0000118245.66976.e1

14. Carson CC III, Mulcahy JJ, Harsch MR. "Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of follow-up." J Urol. 2011;185(2):614–618. doi:10.1016/j.juro.2010.09.094

15. Towe M, Huynh LM, Osman MM, et al. "Impact of antimicrobial dipping solutions on postoperative infection rates in patients with diabetes undergoing primary insertion of a Coloplast Titan inflatable penile prosthesis." J Sex Med. 2020;17(10):2077–2083. doi:10.1016/j.jsxm.2020.07.009

16. Wolter CE, Hellstrom WJG. "The hydrophilic-coated inflatable penile prosthesis: 1-year experience." J Sex Med. 2004;1(2):221–224. doi:10.1111/j.1743-6109.2004.04032.x

17. Serefoglu EC, Mandava SH, Gokce A, et al. "Long-term revision rate due to infection in hydrophilic-coated inflatable penile prostheses: 11-year follow-up." J Sex Med. 2012;9(8):2182–2186. doi:10.1111/j.1743-6109.2012.02830.x

18. Karpman E, Griggs R, Twomey C, Henry GD. "Dipping Titan implants in Irrisept solution (0.05% chlorhexidine gluconate) and exposure to various aerobic, anaerobic, and fungal species." J Sex Med. 2023;20(7):1025–1031. doi:10.1093/jsxmed/qdad055

19. Ivan SJ, Abou Chawareb E, Hammad M, et al. "0.05% chlorhexidine gluconate is not associated with infection in antibiotic-impregnated inflatable penile prosthesis surgery: results from a large multi-institutional collaborative." J Sex Med. 2026;23(1):qdaf368. doi:10.1093/jsxmed/qdaf368

20. Ivan SJ, Abou Chawareb E, Hammad M, et al. "Intraoperative 0.05% chlorhexidine gluconate utilization is associated with an increased incidence of infection in hydrophilic inflatable penile prosthesis surgery: a multi-institutional cohort study." J Urol. 2026;215(4):460–471. doi:10.1097/JU.0000000000004853

21. Simhal R, Alagga A, Gao T, et al. "Comparative efficacy of antibiotic solutions versus 0.05% chlorhexidine gluconate on hydrophilic IPP surfaces: an in vitro study." J Sex Med. 2024.

22. Helo S, Bonakdar Hashemi M, Ziegelmann MJ, et al. "Chlorhexidine gluconate application, diabetes, revision surgery, and extended operative time increase risk for penile implant infection." J Sex Med. 2025;22:508–516. doi:10.1093/jsxmed/qdaf009

23. Lim R, Liang J, Bole R, et al. "Minocycline-rifampin-impregnated penile prosthesis surfaces retain antimicrobial activity following irrigation with 0.05% chlorhexidine gluconate and antibiotic solutions." J Sex Med. 2024.

24. Manka MG, Yang D, Andrews JR, et al. "5% povidone-iodine wound irrigation is associated with markedly increased risk of penile prosthesis infection: a matched case-control analysis." J Sex Med. 2020.

25. Sun HH, Callegari M, Zhou E, et al. "Trends over 20 years of antimicrobial prophylaxis for artificial urinary sphincter surgery." Neurourol Urodyn. 2023;42(6):1421–1430. doi:10.1002/nau.25206

26. Nicolle LE, Gupta K, Bradley SF, et al. "Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America." Clin Infect Dis. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121